← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #232 OF 1,000 MOST-CITED

Procedures to be written and followed

FDA cited this observation 99 times across 95 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs99
BY FISCAL YEAR
FY20266
FY20255
FY20248
FY20233
FY20226
FY20216
FY20208
FY201923
FY201821
FY201713

How FDA worded it — real examples

Procedures describing the handling of all written and oral complaints regarding a drug product are not followed.

MD Logistics, LLC · Plainfield, Indiana · Drugs · 2026-04-03

Procedures describing the handling of all written and oral complaints regarding a drug product are not established.

MPP PHARMA LLC · Kansas City, Missouri · Drugs · 2026-04-02

Procedures describing the handling of all written and oral complaints regarding a drug product are not established and followed.

CSL Behring GmbH · Marburg · Drugs · 2026-02-18

Procedures describing the handling of all written and oral complaints regarding a drug product are not established, written and followed.

K.C. Pharmaceuticals, Inc · Pomona, California · Drugs · 2026-02-13

Procedures describing the handling of all written and oral complaints regarding a drug product are not followed.

Nice-Pak Products, LLC · Saint Louis, Missouri · Drugs · 2026-02-05

Procedures describing the handling of all written and oral complaints regarding a drug product are not established and written.

KaryoLogic Inc · Durham, North Carolina · Drugs · 2025-12-19

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality systemPharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →